Gene Signature Identifies Breast Cancer Patients Who Will Respond To Chemotherapy
Main Category: Breast CancerAlso Included In: Cancer / Oncology
Article Date: 14 May 2009 - 5:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Researchers have identified a genetic signature that can predict which breast cancer patients will respond well to treatment with epirubicin, a widely used form of chemotherapy. Although among the most effective chemotherapies in breast cancer, a small proportion of women suffer severe side-effects.
By identifying those women who are most likely to benefit from treatment, doctors may be able to ensure fewer women are unnecessarily exposed to that risk. The new study shows that this goal can be achieved by developing more sophisticated ways to use older drugs.
Source
European Society for Medical Oncology
Visit our breast cancer section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/150066.php>
APA
http://www.medicalnewstoday.com/releases/150066.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




